The lack of clinical efficacy of PD-L1 blockade in PC patients suggests that it may be necessary to address the immunosuppressive effects by employing immune co-stimulatory agents such as agonistic OX40 immunotherapy, combined with RT or hyperthermia (HT) [10,39]. Here, TNFRSF4 is linked to pachyonychia congenita.